Symbols / MYGN Stock $4.78 -0.21% Myriad Genetics, Inc.

Healthcare • Diagnostics & Research • United States • NMS
MYGN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Diagnostics & Research
CEO Mr. Samraat S. Raha
Exch · Country NMS · United States
Market Cap 451.44M
Enterprise Value 296.27M
Income -230.00M
Sales 557.00M
FCF (ttm) -46.06M
Book/sh 3.94
Cash/sh 1.61
Employees 2,700
Insider 10d —
IPO Oct 06, 1995
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 30.66
PEG 1.24
P/S 0.81
P/B 1.21
P/C —
EV/EBITDA -2.65
EV/Sales 0.53
Quick Ratio 1.65
Current Ratio 2.67
Debt/Eq 32.84
LT Debt/Eq —
EPS (ttm) -3.95
EPS next Y 0.16
EPS Growth —
Revenue Growth -20.80%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-05
Earnings (prior) 2026-02-23
ROA -7.65%
ROE -23.51%
ROIC —
Gross Margin 68.06%
Oper. Margin -21.41%
Profit Margin -41.29%
Shs Outstand 94.44M
Shs Float 85.14M
Insider Own 3.33%
Instit Own 102.98%
Short Float 8.95%
Short Ratio 3.90
Short Interest 8.24M
52W High 8.59
vs 52W High -44.35%
52W Low 3.76
vs 52W Low 27.13%
Beta 1.64
Impl. Vol. 50.25%
Rel Volume 0.44
Avg Volume 1.69M
Volume 735.81K
Target (mean) $7.42
Tgt Median $6.00
Tgt Low $4.00
Tgt High $18.00
# Analysts 9
Recom Hold
Prev Close $4.79
Price $4.78
Change -0.21%
About

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$7.42
Mean price target
2. Current target
$4.78
Latest analyst target
3. DCF / Fair value
$-8.78
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.78
Low
$4.00
High
$18.00
Mean
$7.42

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-02-24 main UBS Neutral → Neutral $6
2026-02-24 main Wells Fargo Equal-Weight → Equal-Weight $6
2025-11-11 main Piper Sandler Overweight → Overweight $9
2025-11-05 main Wells Fargo Equal-Weight → Equal-Weight $7
2025-11-04 main TD Cowen Hold → Hold $9
2025-11-04 main UBS Neutral → Neutral $8
2025-05-21 down Scotiabank Sector Outperform → Sector Perform $6
2025-05-15 main Piper Sandler Overweight → Overweight $9
2025-05-08 down Wells Fargo Overweight → Equal-Weight $6
2025-05-07 main Goldman Sachs Buy → Buy $8
2025-05-07 main UBS Neutral → Neutral $7
2025-05-07 reit Raymond James Outperform → Outperform $10
2025-04-17 main Goldman Sachs Buy → Buy $14
2025-04-09 down Guggenheim Buy → Neutral —
2025-04-01 main Scotiabank Sector Outperform → Sector Outperform $20
2025-03-12 up Piper Sandler Neutral → Overweight $13
2025-03-04 main Piper Sandler Neutral → Neutral $12
2025-03-03 main B of A Securities Underperform → Underperform $11
2025-02-25 reit Raymond James Outperform → Outperform $19
2025-02-25 main UBS Neutral → Neutral $16
News
RSS: Latest MYGN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-12 FOX JENNIFER LYNNE Officer — 195,876 $0.00 $0
2026-03-12 MUZZEY DALE Officer — 173,196 $0.00 $0
2026-03-12 DONNELLY BRIAN J Officer — 226,804 $0.00 $0
2026-03-12 WHEELER BENJAMIN RICHARD Chief Financial Officer — 206,186 $0.00 $0
2026-03-12 SOLAIMAN SHEREEN Officer — 173,196 $0.00 $0
2026-03-12 VERRATTI MARK S Chief Operating Officer — 247,423 $0.00 $0
2026-03-12 RAHA SAMRAAT S. Chief Executive Officer — 618,557 $0.00 $0
2026-03-09 RAHA SAMRAAT S. Chief Executive Officer — 40,000 $5.00 $199,844
2026-02-27 PHANSTIEL S LOUISE Director — 104,507 $4.66 $494,722
2026-02-02 MUZZEY DALE Officer — 23,697 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
824.50
-1.56%
837.60
+11.21%
753.20
+11.03%
678.40
Operating Revenue
824.50
-1.56%
837.60
+11.21%
753.20
+11.03%
678.40
Cost Of Revenue
247.90
-1.70%
252.20
+6.77%
236.20
+16.93%
202.00
Reconciled Cost Of Revenue
247.90
-1.70%
252.20
+6.77%
236.20
+16.93%
202.00
Gross Profit
576.60
-1.50%
585.40
+13.23%
517.00
+8.52%
476.40
Operating Expense
644.40
-4.31%
673.40
+1.78%
661.60
+10.25%
600.10
Research And Development
106.80
-5.82%
113.40
+27.85%
88.70
+3.86%
85.40
Selling General And Administration
537.60
-4.00%
560.00
-2.25%
572.90
+11.31%
514.70
Selling And Marketing Expense
280.80
-1.16%
284.10
-1.76%
289.20
+8.40%
266.80
General And Administrative Expense
256.80
-6.92%
275.90
-2.75%
283.70
+14.44%
247.90
Other Gand A
256.80
-6.92%
275.90
-2.75%
283.70
+14.44%
247.90
Total Expenses
892.30
-3.60%
925.60
+3.10%
897.80
+11.93%
802.10
Operating Income
-67.80
+22.95%
-88.00
+39.14%
-144.60
-16.90%
-123.70
Total Operating Income As Reported
-387.20
-213.52%
-123.50
+52.02%
-257.40
-83.07%
-140.60
EBITDA
-330.90
-456.13%
-59.50
+69.86%
-197.40
-133.06%
-84.70
Normalized EBITDA
-11.50
+52.08%
-24.00
+71.63%
-84.60
-24.78%
-67.80
Reconciled Depreciation
53.70
-12.25%
61.20
-1.13%
61.90
+17.46%
52.70
EBIT
-384.60
-218.64%
-120.70
+53.45%
-259.30
-88.72%
-137.40
Total Unusual Items
-319.40
-799.72%
-35.50
+68.53%
-112.80
-567.46%
-16.90
Total Unusual Items Excluding Goodwill
-319.40
-799.72%
-35.50
+68.53%
-112.80
-567.46%
-16.90
Special Income Charges
-319.40
-799.72%
-35.50
+68.53%
-112.80
-567.46%
-16.90
Other Special Charges
—
-21.30
-118.88%
112.80
—
Impairment Of Capital Assets
319.40
+462.32%
56.80
0.00
-100.00%
16.90
Net Income
-365.90
-187.43%
-127.30
+51.65%
-263.30
-135.09%
-112.00
Pretax Income
-395.10
-219.92%
-123.50
+52.90%
-262.20
-86.49%
-140.60
Net Non Operating Interest Income Expense
-8.70
-690.91%
-1.10
-175.00%
-0.40
+33.33%
-0.60
Interest Expense Non Operating
10.50
+275.00%
2.80
-3.45%
2.90
-9.38%
3.20
Net Interest Income
-8.70
-690.91%
-1.10
-175.00%
-0.40
+33.33%
-0.60
Interest Expense
10.50
+275.00%
2.80
-3.45%
2.90
-9.38%
3.20
Interest Income Non Operating
1.80
+5.88%
1.70
-32.00%
2.50
-3.85%
2.60
Interest Income
1.80
+5.88%
1.70
-32.00%
2.50
-3.85%
2.60
Other Income Expense
-318.60
-826.16%
-34.40
+70.65%
-117.20
-619.02%
-16.30
Other Non Operating Income Expenses
0.80
-27.27%
1.10
+125.00%
-4.40
-833.33%
0.60
Tax Provision
-29.20
-868.42%
3.80
+245.45%
1.10
+103.85%
-28.60
Tax Rate For Calcs
0.00
-64.76%
0.00
+0.00%
0.00
+3.24%
0.00
Tax Effect Of Unusual Items
-23.64
-217.04%
-7.46
+68.53%
-23.69
-589.07%
-3.44
Net Income Including Noncontrolling Interests
-365.90
-187.43%
-127.30
+51.65%
-263.30
-135.09%
-112.00
Net Income From Continuing Operation Net Minority Interest
-365.90
-187.43%
-127.30
+51.65%
-263.30
-135.09%
-112.00
Net Income From Continuing And Discontinued Operation
-365.90
-187.43%
-127.30
+51.65%
-263.30
-135.09%
-112.00
Net Income Continuous Operations
-365.90
-187.43%
-127.30
+51.65%
-263.30
-135.09%
-112.00
Minority Interests
—
—
—
0.00
Normalized Income
-70.14
+29.34%
-99.25
+43.02%
-174.19
-76.77%
-98.54
Net Income Common Stockholders
-365.90
-187.43%
-127.30
+51.65%
-263.30
-135.09%
-112.00
Diluted EPS
-3.95
-180.14%
-1.41
+55.66%
-3.18
-128.78%
-1.39
Basic EPS
-3.95
-180.14%
-1.41
+55.66%
-3.18
-128.78%
-1.39
Basic Average Shares
92.60
+2.21%
90.60
+9.42%
82.80
+2.73%
80.60
Diluted Average Shares
92.60
+2.21%
90.60
+9.42%
82.80
+2.73%
80.60
Diluted NI Availto Com Stockholders
-365.90
-187.43%
-127.30
+51.65%
-263.30
-135.09%
-112.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
706.60
-31.24%
1,027.60
-10.37%
1,146.50
-4.35%
1,198.70
Current Assets
332.60
+11.61%
298.00
-4.97%
313.60
+14.20%
274.60
Cash Cash Equivalents And Short Term Investments
149.60
+46.09%
102.40
-27.32%
140.90
+22.63%
114.90
Cash And Cash Equivalents
149.60
+46.09%
102.40
-22.48%
132.10
+132.16%
56.90
Cash Equivalents
—
—
2.20
-33.33%
3.30
Cash Financial
—
—
129.90
+142.35%
53.60
Other Short Term Investments
—
0.00
-100.00%
8.80
-84.83%
58.00
Receivables
115.30
-4.87%
121.20
+6.04%
114.30
+12.50%
101.60
Accounts Receivable
115.30
-4.87%
121.20
+6.04%
114.30
+12.50%
101.60
Inventory
30.60
+11.27%
27.50
+25.00%
22.00
+9.45%
20.10
Prepaid Assets
12.00
-26.83%
16.40
-3.53%
17.00
-3.41%
17.60
Other Current Assets
25.10
-17.70%
30.50
+57.22%
19.40
-4.90%
20.40
Total Non Current Assets
374.00
-48.74%
729.60
-12.40%
832.90
-9.87%
924.10
Net PPE
163.40
-5.22%
172.40
-4.54%
180.60
-3.58%
187.30
Gross PPE
251.30
-10.89%
282.00
-6.16%
300.50
+1.35%
296.50
Accumulated Depreciation
-87.90
+19.80%
-109.60
+8.59%
-119.90
-9.80%
-109.20
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
—
—
147.60
+18.36%
124.70
Other Properties
170.90
-16.02%
203.50
-2.72%
209.20
-8.49%
228.60
Leases
80.40
+2.42%
78.50
-14.02%
91.30
+34.46%
67.90
Goodwill And Other Intangible Assets
205.00
-62.64%
548.70
-13.85%
636.90
-4.44%
666.50
Goodwill
51.60
-81.98%
286.30
-0.38%
287.40
+0.21%
286.80
Other Intangible Assets
153.40
-41.54%
262.40
-24.92%
349.50
-7.95%
379.70
Investments And Advances
—
—
0.00
-100.00%
54.80
Other Non Current Assets
5.60
-34.12%
8.50
-44.81%
15.40
-0.65%
15.50
Total Liabilities Net Minority Interest
338.60
+3.71%
326.50
-10.13%
363.30
+16.11%
312.90
Current Liabilities
133.80
-18.46%
164.10
+5.26%
155.90
+13.63%
137.20
Payables And Accrued Expenses
75.70
-12.38%
86.40
-4.00%
90.00
+9.89%
81.90
Payables
55.60
-2.97%
57.30
+13.47%
50.50
-4.54%
52.90
Accounts Payable
30.00
-7.12%
32.30
+25.19%
25.80
-10.42%
28.80
Other Payable
19.90
+0.00%
19.90
-1.00%
20.10
+4.15%
19.30
Current Accrued Expenses
20.10
-30.93%
29.10
-26.33%
39.50
+36.21%
29.00
Pensionand Other Post Retirement Benefit Plans Current
51.20
-10.80%
57.40
+15.49%
49.70
+20.63%
41.20
Total Tax Payable
5.70
+11.76%
5.10
+10.87%
4.60
-4.17%
4.80
Current Debt And Capital Lease Obligation
6.90
-46.09%
12.80
-20.99%
16.20
+14.89%
14.10
Current Capital Lease Obligation
6.90
-46.09%
12.80
-20.99%
16.20
+14.89%
14.10
Current Deferred Liabilities
—
—
—
0.60
Current Deferred Revenue
—
—
—
0.60
Other Current Liabilities
—
7.50
-27.88%
10.40
—
Total Non Current Liabilities Net Minority Interest
204.80
+26.11%
162.40
-21.70%
207.40
+18.04%
175.70
Long Term Debt And Capital Lease Obligation
202.90
+59.14%
127.50
-6.18%
135.90
+3.82%
130.90
Long Term Debt
119.90
+202.78%
39.60
+2.86%
38.50
—
Long Term Capital Lease Obligation
83.00
-5.57%
87.90
-9.75%
97.40
-25.59%
130.90
Tradeand Other Payables Non Current
0.20
-99.39%
32.70
+8.28%
30.20
+12.69%
26.80
Non Current Deferred Liabilities
—
—
—
3.50
Non Current Deferred Taxes Liabilities
—
—
—
3.50
Other Non Current Liabilities
1.70
-22.73%
2.20
-94.67%
41.30
+129.44%
18.00
Stockholders Equity
368.00
-47.51%
701.10
-10.48%
783.20
-11.58%
885.80
Common Stock Equity
368.00
-47.51%
701.10
-10.48%
783.20
-11.58%
885.80
Capital Stock
0.90
+0.00%
0.90
+0.00%
0.90
+12.50%
0.80
Common Stock
0.90
+0.00%
0.90
+0.00%
0.90
+12.50%
0.80
Share Issued
93.50
+2.41%
91.30
+1.56%
89.90
+10.71%
81.20
Ordinary Shares Number
93.50
+2.41%
91.30
+1.56%
89.90
+10.71%
81.20
Additional Paid In Capital
1,489.00
+2.14%
1,457.80
+2.99%
1,415.50
+12.33%
1,260.10
Retained Earnings
-1,122.70
-48.35%
-756.80
-20.22%
-629.50
-71.90%
-366.20
Gains Losses Not Affecting Retained Earnings
0.80
+200.00%
-0.80
+78.38%
-3.70
+58.43%
-8.90
Minority Interest
—
—
—
0.00
Other Equity Adjustments
0.80
+200.00%
-0.80
+78.38%
-3.70
+58.43%
-8.90
Total Equity Gross Minority Interest
368.00
-47.51%
701.10
-10.48%
783.20
-11.58%
885.80
Total Capitalization
487.90
-34.13%
740.70
-9.86%
821.70
-7.24%
885.80
Working Capital
198.80
+48.47%
133.90
-15.09%
157.70
+14.77%
137.40
Invested Capital
487.90
-34.13%
740.70
-9.86%
821.70
-7.24%
885.80
Total Debt
209.80
+49.54%
140.30
-7.76%
152.10
+4.90%
145.00
Capital Lease Obligations
89.90
-10.72%
100.70
-11.36%
113.60
-21.66%
145.00
Net Tangible Assets
163.00
+6.96%
152.40
+4.17%
146.30
-33.29%
219.30
Tangible Book Value
163.00
+6.96%
152.40
+4.17%
146.30
-33.29%
219.30
Available For Sale Securities
—
—
—
54.80
Investmentin Financial Assets
—
—
0.00
-100.00%
54.80
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
1.80
+120.69%
-8.70
+92.16%
-110.90
-4.33%
-106.30
Cash Flow From Continuing Operating Activities
1.80
+120.69%
-8.70
+92.16%
-110.90
-4.33%
-106.30
Net Income From Continuing Operations
-365.90
-187.43%
-127.30
+51.65%
-263.30
-135.09%
-112.00
Depreciation Amortization Depletion
53.70
-12.25%
61.20
-1.13%
61.90
+17.46%
52.70
Depreciation And Amortization
53.70
-12.25%
61.20
-1.13%
61.90
+17.46%
52.70
Other Non Cash Items
11.10
+94.74%
5.70
-85.64%
39.70
+26.43%
31.40
Stock Based Compensation
35.20
-29.32%
49.80
+22.36%
40.70
+6.82%
38.10
Asset Impairment Charge
319.40
+464.31%
56.60
0.00
-100.00%
16.90
Deferred Tax
-32.40
-10700.00%
-0.30
+50.00%
-0.60
+98.12%
-31.90
Deferred Income Tax
-32.40
-10700.00%
-0.30
+50.00%
-0.60
+98.12%
-31.90
Operating Gains Losses
—
—
1.50
—
Gain Loss On Investment Securities
—
—
1.50
—
Net Foreign Currency Exchange Gain Loss
—
—
—
0.00
Change In Working Capital
-19.30
+64.52%
-54.40
-608.41%
10.70
+110.54%
-101.50
Change In Receivables
6.20
+171.26%
-8.70
+30.40%
-12.50
-21.36%
-10.30
Changes In Account Receivables
6.20
+171.26%
-8.70
+30.40%
-12.50
-21.36%
-10.30
Change In Inventory
-3.20
+48.39%
-6.20
-244.44%
-1.80
+37.93%
-2.90
Change In Prepaid Assets
4.60
+243.75%
-3.20
-455.56%
0.90
-60.87%
2.30
Change In Payables And Accrued Expense
-28.90
+20.39%
-36.30
-254.47%
23.50
+126.20%
-89.70
Change In Accrued Expense
-27.50
+32.93%
-41.00
-250.74%
27.20
+131.55%
-86.20
Change In Payable
-1.40
-129.79%
4.70
+227.03%
-3.70
-5.71%
-3.50
Change In Account Payable
-1.40
-129.79%
4.70
+227.03%
-3.70
-5.71%
-3.50
Change In Other Working Capital
—
—
-0.20
+96.00%
-5.00
Change In Other Current Assets
2.00
0.00
-100.00%
0.60
+166.67%
-0.90
Investing Cash Flow
-27.40
-130.25%
-11.90
-137.30%
31.90
+141.16%
-77.50
Cash Flow From Continuing Investing Activities
-27.40
-130.25%
-11.90
-137.30%
31.90
+141.16%
-77.50
Capital Expenditure
-27.40
+7.74%
-29.70
+59.48%
-73.30
-61.81%
-45.30
Capital Expenditure Reported
-27.40
+7.74%
-29.70
+59.48%
-73.30
-61.81%
-45.30
Net Investment Purchase And Sale
0.00
-100.00%
9.00
-91.44%
105.20
+320.80%
25.00
Purchase Of Investment
—
0.00
0.00
+100.00%
-103.20
Sale Of Investment
0.00
-100.00%
9.00
-91.44%
105.20
-17.94%
128.20
Net Business Purchase And Sale
0.00
-100.00%
8.80
0.00
+100.00%
-57.20
Purchase Of Business
—
0.00
0.00
+100.00%
-57.20
Gain Loss On Sale Of Business
—
—
0.00
0.00
Financing Cash Flow
64.20
+967.57%
-7.40
-104.84%
152.90
+2011.25%
-8.00
Cash Flow From Continuing Financing Activities
64.20
+967.57%
-7.40
-104.84%
152.90
+2011.25%
-8.00
Net Issuance Payments Of Debt
84.30
+84200.00%
0.10
-99.75%
39.80
0.00
Issuance Of Debt
165.00
+37.50%
120.00
+50.00%
80.00
0.00
Repayment Of Debt
-80.70
+32.69%
-119.90
-198.26%
-40.20
0.00
Long Term Debt Issuance
165.00
+37.50%
120.00
+50.00%
80.00
0.00
Long Term Debt Payments
-80.70
+32.69%
-119.90
-198.26%
-40.20
0.00
Net Long Term Debt Issuance
84.30
+84200.00%
0.10
-99.75%
39.80
0.00
Short Term Debt Issuance
—
—
—
—
Short Term Debt Payments
—
—
—
—
Net Short Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
0.00
0.00
-100.00%
117.60
0.00
Common Stock Payments
—
—
—
—
Repurchase Of Capital Stock
—
—
—
—
Proceeds From Stock Option Exercised
3.30
-44.07%
5.90
-1.67%
6.00
-4.76%
6.30
Net Other Financing Charges
-23.40
-74.63%
-13.40
-27.62%
-10.50
+26.57%
-14.30
Changes In Cash
38.60
+237.86%
-28.00
-137.89%
73.90
+138.53%
-191.80
Effect Of Exchange Rate Changes
0.80
+180.00%
-1.00
-266.67%
0.60
+200.00%
-0.60
Beginning Cash Position
111.90
-20.58%
140.90
+112.20%
66.40
-74.34%
258.80
End Cash Position
151.30
+35.21%
111.90
-20.58%
140.90
+112.20%
66.40
Free Cash Flow
-25.60
+33.33%
-38.40
+79.15%
-184.20
-21.50%
-151.60
Interest Paid Supplemental Data
8.40
+342.11%
1.90
+35.71%
1.40
0.00
Income Tax Paid Supplemental Data
—
2.70
+42.11%
1.90
+5.56%
1.80
Common Stock Issuance
0.00
0.00
-100.00%
117.60
0.00
Issuance Of Capital Stock
0.00
0.00
-100.00%
117.60
0.00
Sale Of Business
0.00
-100.00%
8.80
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category